Skip to content
Peptide Atlas
All peptides

Cerebrolysin

Tier 1 · Human trials
Also known as FPF-1070 · Cerebrolysin concentrate

Multiple human randomized controlled trials and Cochrane systematic reviews exist (acute ischaemic stroke, vascular dementia, Alzheimer's disease), supporting a Tier 1 rating. However, the human evidence is contested: an individual RCT and a network meta-analysis report benefits in stroke, while multiple Cochrane reviews conclude there is insufficient evidence for routine use and flag increased non-fatal serious adverse events. Many mechanistic, neurotrophic-mimicry, mood, and cognitive-enhancement claims rest on Tier 2 (in vitro/animal) data or Tier 3 manufacturer/vendor materials, and reported composition figures and study/patient counts vary across sources.

Half-life
Not recorded
Routes
Intravenous injection · Intravenous infusion · Intramuscular injection
Goals
Neuroprotection · Cognitive support · Stroke recovery / neurorehabilitation · Dementia (vascular and Alzheimer's type) · Traumatic brain injury recovery · Mood / neuropsychiatric
Cost / mg
Not recorded

How it works

Cerebrolysin is not a single molecule but a liquid preparation made from pig brain tissue, broken down by enzymes into a mix of free amino acids (roughly 75%) and small peptides under about 10,000 daltons (roughly 25%). These small components are thought to be able to cross into the brain and behave like the body's own natural nerve-growth signals (such as BDNF, NGF, GDNF and CNTF), helping nerve cells survive, form new connections, and grow. Researchers propose it protects neurons by reducing cell death, calming inflammation, lowering oxidative stress (free radicals), and supporting blood vessels in the brain. Because peptides are destroyed in the gut, it is given by injection or infusion rather than by mouth. It is approved in many countries for stroke, traumatic brain injury and dementia, but has never been approved by the U.S. FDA, and rigorous reviews disagree on how much real benefit it provides.

Overview

What Cerebrolysin Is

Cerebrolysin (also known as FPF-1070 or Cerebrolysin concentrate) is a parenterally administered, porcine (pig) brain-derived preparation of low-molecular-weight neuropeptides and free amino acids, all below roughly 10,000 Da (10 kDa). It is produced by standardized enzymatic proteolysis of lipid-free brain proteins. Each milliliter of solution contains 215.2 mg of peptide concentrate in aqueous solution, with sodium hydroxide and water for injection as excipients.

It is not a single defined molecule. By weight it is described as approximately 75% free L-amino acids and about 25% biologically active peptides below 10 kDa (an older characterization gives ~85% amino acids / ~15% short amino-acid sequences). A 2023 analytical study (Yang et al., Journal of Chromatography B) using NanoLC-MS characterized the active constituents as a complex mixture of short-chain peptides rather than a single molecular entity.

Cerebrolysin was first developed in the 1940s (reported as 1949 by Austrian professor Gerhart Harrer), refined in the 1970s, received regulatory approval in Austria in 1954, and is manufactured by EVER Neuro Pharma, headquartered in Austria.

Proposed Mechanism

Cerebrolysin is described as a multi-modal neuropeptide/neurotrophic peptidergic drug with a fast onset and a complex, pleiotropic mechanism. Its peptide components are proposed to mimic the biological activity of endogenous neurotrophic factors including BDNF, NGF, GDNF and CNTF, and to activate tropomyosin receptor kinases (TrkA, TrkB) and GFRα1 receptors. It is reported to stimulate endogenous production of BDNF, VEGF and IGF-1 while downregulating TNF-α, and to modify two major signalling pathways — the neurotrophic factor (NTF) and sonic hedgehog (Shh) pathways — that regulate neurogenesis, angiogenesis, dendrite arborisation, axonal sprouting, myelination, and the integrity of the neurovascular unit.

Across preclinical (in vitro and animal) work, Cerebrolysin has been reported to: stabilize neuronal structural integrity via calpain inhibition (~60%, p<0.005) and reduce caspase-3 activity; upregulate anti-apoptotic Bcl-2 and Bcl-xL; modulate PI3K/AKT and GSK3 survival signalling; attenuate glutamate excitotoxicity; reduce microglial activation and IL-1β release (p<0.01); reduce free-radical formation (2,3-DHBA and 2,5-DHBA) after ischemia; enhance neurogenesis in subventricular and hippocampal niches; and improve neuronal energy metabolism. It is also proposed to reduce APP processing and tau hyperphosphorylation. Peptide components are theorized to be small enough to cross the blood-brain barrier and reach neurons directly, with preclinical tracing (Frey et al., Gschanes et al.) detecting molecules in neuronal parenchyma.

Reported Clinical Uses and Evidence

Cerebrolysin is approved for clinical use in many countries (variously cited as 35+, 45+ or over 50), including Austria, Germany, Russia, China and South Korea, for indications such as ischemic stroke, traumatic brain injury and various forms of dementia. It is widely used in Russia, Eastern Europe, China and other Asian and post-Soviet countries, particularly in neurorehabilitation clinics. It has never been approved by the U.S. FDA for any indication and is not registered for sale or distribution in the United States.

Acute ischemic stroke (contested): A randomized placebo-controlled trial of 100 patients treated within 18 hours (30 mL over seven days, then 10 mL until day 30) reported medium-to-large superiority over placebo on change in NIH Stroke Scale at day 30 (Mann-Whitney 0.66; 95% CI 0.55–0.78; P=0.005), with improvements in modified Rankin Scale and Clinical Global Impression; effects on MMSE and Patient Global Satisfaction did not reach significance. A network meta-analysis (35 studies, 18,423 cases) reported reduced mortality and improved neural function versus conventional treatment, but with a higher rate of adverse effects. In contrast, multiple Cochrane systematic reviews across three decades conclude there is insufficient evidence to support routine use in acute ischaemic stroke and probably little to no difference in all-cause death (e.g., RR 0.96, 95% CI 0.65–1.41). A large 2012 trial cast doubt on its usefulness except perhaps in severe cases.

Vascular dementia: A meta-analysis (6 RCTs, 597 participants) and a Cochrane review reported beneficial effects on cognition (e.g., MMSE WMD 1.10; ADAS-cog+ WMD −4.01; SMD 0.36) and global clinical function (response RR ~2.7), though authors note the limited number of trials, varied durations and short follow-up preclude routine recommendation.

Alzheimer's disease: Randomized double-blind trials up to 28 weeks reported superiority over placebo on global and cognitive outcomes, with a comparison of Cerebrolysin, donepezil, or the combination showing benefit for all three versus baseline; it may be useful in combination with donepezil. One trial suggested non-APOE4 carriers were about three times more likely to respond, while in APOE4 carriers it more effectively raised a brain-cell growth/survival protein. Reported memory effects are lower than currently approved Alzheimer's drugs, and dementia-prevention benefit in healthy adults is unknown.

Other reported uses: Reported cognitive/memory improvement in schizophrenia patients and older adults with memory loss; a single trial in 158 infants with severe perinatal brain insult (0.1 mL/kg twice weekly for 5 weeks) reported large gains in social, speech, symbolic and total scores (p<0.001) and proposed equivalence to stem cell therapy for communication defects — a dramatic result from a single study. It is also being explored for cognitive impairment in PTSD given its proposed neurotrophic and anti-inflammatory activity.

The size of the evidence base is stated inconsistently across (largely manufacturer/vendor) sources: 87 studies / 17,000+ patients, 160+ studies / 8,000 patients, or 200+ trials / ~15,000 patients.

Important Caveats

Sources sharply disagree on efficacy in acute ischemic stroke, and manufacturer descriptions of an 'excellent' safety profile conflict with Cochrane findings of increased non-fatal serious adverse events. Many mechanistic and enhancement claims rest on preclinical (in vitro/animal) data or commercial/vendor pages and may not translate to clinical benefit.

What the research shows

295 findings extracted from the 31 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 69 human trial findings, 4 human study findings, 3 animal findings, 10 expert opinion findings and 1 theoretical finding.

  • human trialCerebrolysin dramatically improved infants' communication especially symbolic behavior which positively affected social interaction1

  • human trialIn infants with severe perinatal brain insult, Cerebrolysin group exhibited increases of 65.44% in social scores, 45.54% in speech scores, 358.06% in symbolic scores, and 96.00% in total scores from baseline after 3 months (p<0.001 for all)1

  • human trialCerebrolysin is effective, safe and well-tolerated as shown in clinical studies including randomized, double-blind, controlled trials2

  • human trialA large 2012 trial casts doubts on cerebrolysin's usefulness in stroke, except perhaps in severe cases3

  • human trialCerebrolysin treatment improved cognition and memory in schizophrenia patients3

  • human trialA peptide preparation derived from cerebrolysin improved memory performance but not verbal fluency in older adults with memory loss3

  • human trialThe effect on memory from cerebrolysin was lower than that of currently approved drugs for Alzheimer's disease3

  • human trialHealthy elderly people had better memory performance after one dose of cerebrolysin but this result could have been caused by the placebo effect3

Show the remaining 79

  • human trialIn one trial, Alzheimer's patients without an APOE4 allele were about three times more likely to respond to treatment than APOE4 carriers3

  • human trialIn APOE4 carriers, cerebrolysin was more effective at increasing the level of a protein that enhances brain cell growth and survival3

  • human trialCerebrolysin has an overall beneficial effect on cognitive function in patients with mild-to-moderate Alzheimer's disease3

  • human trialCerebrolysin has beneficial effects in patients with vascular dementia3

  • human trialCerebrolysin may be useful in combination with donepezil3

  • human trialCerebrolysin treatment within 18 hours after acute ischemic stroke onset improved NIH Stroke Scale scores at day 30 compared to placebo4

  • human trialCerebrolysin showed medium to large superiority on NIH Stroke Scale change from baseline to day 30 (Mann-Whitney 0.66; 95% CI 0.55-0.78, P=0.005)4

  • human trialCerebrolysin improved modified Rankin Scale outcomes (Mann-Whitney 0.65; 95% CI 0.54-0.76; P=0.010)4

  • human trialCerebrolysin improved Clinical Global Impression outcomes (Mann-Whitney 0.70; 95% CI 0.55-0.85; P=0.006)4

  • human trialCerebrolysin effects on Mini Mental State Examination did not reach statistical significance4

  • human trialCerebrolysin effects on Patient Global Satisfaction did not reach statistical significance4

  • human trialCerebrolysin showed medium to large superiority compared to placebo on change from baseline in NIH Stroke Scale at day 305

  • human trialCerebrolysin improved modified Rankin Scale compared to placebo with medium to large effect size5

  • human trialCerebrolysin improved Clinical Global Impression compared to placebo with medium to large effect size5

  • human trialEffect sizes in MMSE and PGS did not reach statistical significance5

  • human trialEfficacy has been proven in 87 double-blind-studies and trials with more than 17.000 patients6

  • human trialEarly recovery 7-10 days in stroke patients6

  • human trialImprovement of motor functions in stroke patients6

  • human trialRegained independence in stroke patients6

  • human trialIncreased quality of life in stroke patients6

  • human trialImprovement of cognitive functions in stroke patients6

  • human trialHigher survival rate in stroke patients6

  • human trialEffective treatment after traumatic brain injury6

  • human trialSaves lives in TBI patients6

  • human trialEarly recovery in TBI patients6

  • human trialBetter quality of life in TBI patients6

  • human trialImprovement of memory and concentration in TBI patients6

  • human trialImprovement of cognitive performance in neurocognitive disorders6

  • human trialHigher quality of life in neurocognitive disorders6

  • human trialProlong active and independent life in neurocognitive disorders6

  • human trialPrevention of behavioral disorders in neurocognitive disorders6

  • human trialCerebrolysin is effective, safe and well-tolerated as shown in clinical studies including randomized, double-blind, controlled trials7

  • human trialCerebrolysin treatment reduced mortality in patients with acute ischemic stroke compared with conventional treatment10

  • human trialCerebrolysin improved neural function in acute ischemic stroke patients compared with conventional treatment10

  • human trialCerebrolysin or Cortexin probably result in little to no difference in all-cause death in acute ischaemic stroke11

  • human trialCerebrolysin or similar peptide mixtures may result in little to no difference in non-death attrition, but the evidence is very uncertain, with a considerable level of heterogeneity11

  • human trialModerate-certainty evidence indicates that Cerebrolysin or Cerebrolysin-like peptide mixtures derived from cattle brain probably have no beneficial effect on preventing all-cause death in acute ischaemic stroke11

  • human trialCerebrolysin or Cortexin probably result in little to no difference in all-cause death12

  • human trialCerebrolysin or similar peptide mixtures may result in little to no difference in non-death attrition12

  • human trialCerebrolysin or Cerebrolysin-like peptide mixtures derived from cattle brain probably have no beneficial effect on preventing all-cause death in acute ischaemic stroke12

  • human trialCerebrolysin probably results in little to no difference in all-cause death13

  • human trialCombining the MMSE and ADAS-cog+ data, there was a beneficial effect of Cerebrolysin on cognitive function14

  • human trialThere was a beneficial effect of Cerebrolysin on global function measured by CIBIC+ or CGI14

  • human trialCourses of intravenous Cerebrolysin improved cognition and general function in people living with vascular dementia, with no suggestion of adverse effects14

  • human trialNo difference in all-cause death between cerebrolysin and placebo groups in acute ischaemic stroke treatment15

  • human trialCerebrolysin does not demonstrate clinical benefits for treating acute ischaemic stroke15

  • human trialNo difference in all-cause death between cerebrolysin and placebo groups in acute ischaemic stroke16

  • human trialCerebrolysin does not demonstrate clinical benefits for treating acute ischaemic stroke16

  • human trialThere was no difference in the number of deaths between Cerebrolysin and placebo groups in acute ischaemic stroke17

  • human trialMeta-analyses revealed a beneficial effect of Cerebrolysin on general cognitive function measured by MMSE with weighted mean difference of 1.10 (95% CI 0.37 to 1.82)18

  • human trialCerebrolysin improved cognitive function on ADAS-cog+ with WMD -4.01 (95% CI -5.36 to -2.66)18

  • human trialCerebrolysin improved patients' global clinical function with response rates showing relative risk of 2.71 (95% CI 1.83 to 4.00)18

  • human trialThere is insufficient evidence to recommend Cerebrolysin as a routine treatment for vascular dementia due to limited number of included trials, wide variety of treatment durations and short-term follow-up18

  • human trialNo difference in death between cerebrolysin and placebo groups (6/78 versus 6/68)19

  • human trialThere is not enough evidence to evaluate the effect of cerebrolysin on survival and dependency in people with acute ischaemic stroke19

  • human trialIn several randomized, double-blind trials of up to 28 weeks' duration in patients with Alzheimer's disease, Cerebrolysin was superior to placebo in improving global outcome measures and cognitive ability20

  • human trialA large, randomized comparison of Cerebrolysin, donepezil or combination therapy showed beneficial effects on global measures and cognition for all three treatment groups compared with baseline20

  • human trialCerebrolysin has shown beneficial effects on global measures and cognition in patients with vascular dementia20

  • human trialThe 2023 Cochrane review—pooling 7 RCTs and 1,773 participants—found no evidence of benefit on all-cause death and a statistically significant increase in non-fatal serious adverse events (RR 2.39)29

  • human trialCochrane reviews across three decades find insufficient evidence for routine use29

  • human trialIndividual randomized controlled trials have shown significant benefits in functional recovery, particularly in stroke rehabilitation and cognitive outcomes in dementia30

  • human studyCerebrolysin has been shown to improve outcomes after ischemic stroke8

  • human studyNumerous clinical studies have shown positive effect of Cerebrolysin on motor and cognitive improvement of patients21

  • human studyAcute stroke benefit observed within 24-72 hours of initiation in trial protocols26

  • human studyCognitive and functional improvements typically manifest over 4-12 weeks of repeated courses26

  • animalExperimental studies show Cerebrolysin enhances functional recovery accompanied by reduction in infarct volume5

  • animalGerbils treated with FPF 1070 revealed significant protection of CA1 neurons when it was applied 2 hrs before the occlusion24

  • animalNo clear beneficial effects were observed when FPF 1070 was administered immediately after the recirculation24

  • expert opinionRoutine administration of Cerebrolysin to people with acute ischaemic stroke cannot be supported by the available evidence from RCTs17

  • expert opinionCerebrolysin is clinically proven and of European/Austrian quality25

  • expert opinionMultiple randomized controlled trials have demonstrated cognitive and functional improvements27

  • expert opinionResearch suggests improvements in memory, focus, and cognitive processing27

  • expert opinionSome studies report anxiolytic and mood-stabilizing effects27

  • expert opinionCerebrolysin is one of the most extensively studied neuropeptide preparations in clinical medicine, with data from more than 200 clinical trials and approximately 15,000 patients across multiple neurological conditions28

  • expert opinionCerebrolysin is a porcine brain-derived neuropeptide extract approved in more than 50 countries for stroke and dementia, but not FDA-approved for any indication in the United States29

  • expert opinionThe clinical evidence base comprises over 160 clinical studies enrolling more than 8000 patients30

  • expert opinionTwo Cochrane systematic reviews concluded that the evidence for clinically meaningful benefits is uncertain, citing moderate-to-low quality evidence30

  • expert opinionThere is debate regarding which neuroprotective agents to use in neurorehabilitation of stroke patients in terms of both efficacy and safety31

  • theoreticalThe normothymic effect of Cerebrolysin is due to stabilization of endorphinergic and dopaminergic neurotransmission22

How it works

Based on 6 human trial findings, 19 animal findings, 20 in vitro findings, 52 expert opinion findings and 1 theoretical finding.

  • human trialCerebrolysin is a porcine brain-derived preparation of low-molecular-weight neuropeptides (10 kDa) and free amino acids that exhibits pharmacodynamic properties similar to those of naturally occurring neurotrophic factors1

  • human trialCerebrolysin's mechanism of action is thought to be inhibition of apoptosis1

  • human trialCerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from porcine brain12

  • human trialCerebrolysin has potential neuroprotective properties12

  • human trialCerebrolysin has potential neurotrophic and pro-cognitive effects18

  • human trialCerebrolysin is a parenterally administered, porcine brain-derived peptide preparation that has pharmacodynamic properties similar to those of endogenous neurotrophic factors20

  • animalCerebrolysin has been shown to improve synaptic plasticity and induce neurogenesis in a mouse model of Alzheimer's disease1

  • animalIn preclinical studies, cerebrolysin lessened cognitive impairment3

Show the remaining 90

  • animalIn preclinical studies, cerebrolysin reduced the plaques and tangles common in Alzheimer's patients3

  • animalCerebrolysin stabilizes neuronal structural integrity via inhibition of calpain4

  • animalCerebrolysin induces neuronal sprouting and supports formation of neuronal networks4

  • animalExperimental studies show Cerebrolysin stabilizes neuronal structural integrity via inhibition of calpain5

  • animalExperimental studies show Cerebrolysin supports neuronal network formation by inducing neuronal sprouting and neurogenesis5

  • animalCerebrolysin mechanism involves modulation of phosphatidylinositol-3-kinase (PI3)/AKT and glycogen synthase kinase 3 pathways5

  • animalCerebrolysin significantly reduces the formation of free radicals6

  • animalCerebrolysin reduces the production of free radicals (2,3-DHBA and 2,5-DHBA) following experimentally induced ischemia in an in-vivo animal model6

  • animalPreclinical studies by Frey et al. and Gschanes et al. demonstrated that Cerebrolysin molecules pass through the vessels into the neuronal parenchyma21

  • animalThe 2,5-DHBA contents in the postischemic reperfused brain was significantly reduced when FPF 1070 was administered 2 hr. before the occlusion24

  • animalHydroxyl radicals are produced in the postischemic-reperfused brain and hydroxyl radical scavenging action of FPF 1070 played an important role in preventing delayed neuronal death24

  • animalPreclinical work demonstrates effects consistent with BDNF, NGF, and GDNF signaling26

  • animalUpregulation of neuronal survival pathways (PI3K/Akt)26

  • animalInhibition of calcium-dependent proteases (calpains) and caspase-3-mediated apoptosis26

  • animalAttenuation of glutamate excitotoxicity26

  • animalEnhancement of neurogenesis in subventricular and hippocampal niches26

  • animalAnti-inflammatory modulation of microglia, reduction of oxidative stress, and improvement of energy metabolism in neurons26

  • in vitroIn preclinical studies, cerebrolysin protected neurons and brain slices from damage3

  • in vitroIn preclinical studies, cerebrolysin reduced inflammation3

  • in vitroIn preclinical studies, cerebrolysin promoted the formation of new neural connections (synapses)3

  • in vitroCerebrolysin reduces apoptosis by decreasing calpain and caspase-3 activity6

  • in vitroCerebrolysin inhibits calpain in vitro by about 60%6

  • in vitroCerebrolysin decreases the number of neuronal progenitor cells expressing caspase-3 by a factor of 2.56

  • in vitroCerebrolysin inhibits pro-inflammatory cytokines like IL-1β and reduces microglial activation6

  • in vitroCerebrolysin decreases the level of lipopolysaccharide induced IL-1β release in primary microglial cell culture6

  • in vitroCerebrolysin contains considerable amounts of Leu- and Met-enkephalins, partial analogues of enkephalins, and peptide fragments of beta-lipotropin22

  • in vitroCerebrolysin peptides stimulate the endorphinergic system contributing to normothymic action and increase in brain-derived neurotrophic factor (BDNF) levels22

  • in vitroSpecific inhibition of kinases ABL1, PINK1, CDK5 and arginine N-methyltransferase PRMT5 by cerebrolysin peptides has multidirectional effect on dopaminergic system, helping to stabilize mood22

  • in vitroCerebrolysin peptides do not directly affect serotonergic, adrenergic, or GABAergic systems22

  • in vitroFPF-1070 (Cerebrolysin) significantly promoted neurite outgrowth in DRG and ST neurons at all concentrations examined, in comparison with phosphate buffered saline-treated negative controls23

  • in vitroThe effect of FPF-1070 on neurite outgrowth in DRG and ST neurons was not as significant as that observed for nerve growth factor-treated positive controls23

  • in vitroFPF-1070 exhibited an inverted U relationship between concentration and effectiveness in DRG and ST neurons23

  • in vitroFPF-1070 did not affect neurite outgrowth in CG neurons although ciliary neurotrophic factor-treated positive controls showed striking neurite outgrowth23

  • in vitroFPF-1070 has different neurotrophic effects depending on the subpopulation of neurons23

  • in vitroCerebrolysin (FPF1070) is an extract from pig brain obtained after enzymic digestion, containing free amino acids (85%) and low-molecular weight amino acid sequences (15%)24

  • in vitroA 2023 analytical study by Yang and colleagues, published in the Journal of Chromatography B, used NanoLC-MS mass spectrometry to characterize the active peptide constituents and identified a complex mixture of short-chain peptides rather than a single defined molecular entity29

  • in vitroAn independent 2024 in-vitro study published in Cureus found that Cerebrolysin upregulated BDNF expression in affected neural cells alongside citicoline29

  • expert opinionCerebrolysin improves the brain's ability for self-repair by stimulating neurorecovery2

  • expert opinionCerebrolysin is a neurotrophic peptidergic drug with multimodal pharmacological properties and is indicated for the treatment of acute and chronic central nervous system (CNS) disorders2

  • expert opinionCerebrolysin has shown to modify two major signalling pathways: the neurotrophic factor (NTF) and sonic hedgehog (Shh) signalling pathway2

  • expert opinionThese pathways regulate on a molecular level the cellular processes of neurogenesis, angiogenesis, dendrite arborisation, axonal sprouting, myelination, and integrity of the neurovascular unit2

  • expert opinionCerebrolysin targets protection against excitotoxicity2

  • expert opinionCerebrolysin reduces free radicals2

  • expert opinionCerebrolysin reduces pro-apoptotic enzymes2

  • expert opinionCerebrolysin modulates inflammatory response2

  • expert opinionCerebrolysin improves BBB integrity2

  • expert opinionCerebrolysin prevents formation of toxic protein aggregates and lowers the level of inflammatory processes in the early post-acute phase2

  • expert opinionCerebrolysin is a neuropeptide preparation with neuroprotective and neuroplastic properties4

  • expert opinionCerebrolysin is a neuropeptide preparation with neuroprotective and neuroplastic properties similar to endogenous neurotrophic factors5

  • expert opinionCerebrolysin is a multi-modal neuropeptide drug with a fast onset of action7

  • expert opinionCerebrolysin improves the brain's ability for self-repair by stimulating neurorecovery7

  • expert opinionCerebrolysin is a neurotrophic peptidergic drug with multimodal pharmacological properties7

  • expert opinionCerebrolysin has shown to modify two major signalling pathways: the neurotrophic factor (NTF) and sonic hedgehog (Shh) signalling pathway7

  • expert opinionThese pathways regulate neurogenesis, angiogenesis, dendrite arborisation, axonal sprouting, myelination, and integrity of the neurovascular unit7

  • expert opinionCerebrolysin supports neuroplasticity7

  • expert opinionCerebrolysin supports neurogenesis7

  • expert opinionCerebrolysin is a combination of amino acids and peptides that mimic the biological functions of neurotrophic factors8

  • expert opinionCerebrolysin has a complex, multimodal and pleiotropic mechanism of action8

  • expert opinionPossible pathogenetic mechanisms underlying PTSD are the development of neuroinflammation, oxidative stress and decreased production of neurotrophic factors9

  • expert opinionCerebrolysin has powerful neurotrophic and anti-inflammatory activity9

  • expert opinionCerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from porcine brain that has potential neuroprotective properties13

  • expert opinionCerebrolysin is a porcine brain-derived preparation that is said to have neurotrophic and neuroprotective activity14

  • expert opinionCerebrolysin has potential neuroprotective and neurotrophic properties15

  • expert opinionCerebrolysin has potential neuroprotective and neurotrophic properties16

  • expert opinionCerebrolysin has potential neuroprotective and neurotrophic properties17

  • expert opinionCerebrolysin has proposed neuroprotective and neurotrophic properties19

  • expert opinionCerebrolysin plays a protective and restorative role for the vasculature in the brain21

  • expert opinionCerebrolysin has vascular protective function in addition to effects on parenchymal cells21

  • expert opinionCerebrolysin improves the brain's ability for self-repair by stimulating neurorecovery25

  • expert opinionCerebrolysin is a porcine brain-derived neuropeptide preparation containing a mixture of neurotrophic peptide fractions including BDNF-, NGF-, CNTF-, and GDNF-like fragments (<10kDa)27

  • expert opinionMulti-target neurotrophic action via BDNF, NGF, GDNF-like peptide fractions; activates TrkB, TrkA, and GFRα1 receptors27

  • expert opinionReduces amyloid precursor protein (APP) processing and tau hyperphosphorylation27

  • expert opinionPromotes neuroplasticity, synaptogenesis, and neuroprotection27

  • expert opinionMay protect neurons from oxidative stress and inflammatory damage27

  • expert opinionCerebrolysin is a lipid-free neuropeptide preparation created through standardized enzymatic breakdown of purified porcine (pig) brain proteins28

  • expert opinionThe result is a complex mixture of low-molecular-weight neuropeptides and free amino acids – all below 10,000 Daltons in size28

  • expert opinionThe peptide complex contains fragments associated with BDNF (brain-derived neurotrophic factor) that supports neuronal survival, synaptic regulation, learning, and memory formation28

  • expert opinionThe peptide complex contains fragments associated with NGF (nerve growth factor) that promotes survival of sensory neurons and supports acetylcholine signaling28

  • expert opinionThe peptide complex contains fragments associated with GDNF (glial cell line-derived neurotrophic factor) that aids axonal regeneration and helps prevent neuronal apoptosis28

  • expert opinionThe peptide complex contains fragments associated with CNTF (ciliary neurotrophic factor) that plays a role in protecting motor neurons from degeneration28

  • expert opinionThe preparation consists of a heterogeneous mixture of low-molecular-weight neuropeptides and free amino acids derived from enzymatic breakdown of porcine brain proteins29

  • expert opinionThe core hypothesis behind Cerebrolysin is that its neuropeptide constituents mimic the effects of endogenous neurotrophic factors, specifically brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and glial cell line-derived neurotrophic factor (GDNF)29

  • expert opinionA 2023 narrative review by Rejdak, Sienkiewicz-Jarosz, Bienkowski, and Alvarez summarized proposed mechanisms including promotion of neurogenesis, synaptic plasticity, angiogenesis, anti-inflammatory signaling, and modulation of amyloid-beta and tau pathways relevant to Alzheimer's disease29

  • expert opinionAll peptide components are small enough to cross the blood-brain barrier30

  • expert opinionThe peptide components of Cerebrolysin mimic the biological activity of endogenous neurotrophic factors including BDNF, NGF, GDNF, and CNTF30

  • expert opinionPeptide fragments activate tropomyosin receptor kinases (TrkA and TrkB)30

  • expert opinionCerebrolysin stimulates endogenous production of BDNF, VEGF, and IGF-1 while downregulating TNF-alpha30

  • expert opinionCerebrolysin protects neurons from programmed cell death through upregulation of anti-apoptotic proteins Bcl-2 and Bcl-xL and downregulation of pro-apoptotic mediators30

  • expert opinionCerebrolysin is described as a neuroprotective agent that can inhibit neuronal death and halt or decelerate neuronal loss31

  • theoreticalCerebrolysin is small enough to pass the blood brain barrier (BBB)21

Dosing

Based on 6 human trial findings and 8 expert opinion findings.

  • human trialCerebrolysin was administered twice-weekly at 0.1 mL/kg body weight for 5 weeks (total of ten injections)1

  • human trialIn clinical studies, cerebrolysin doses of 30 ml/day were delivered intravenously3

  • human trialIn the subgroup of dosing schedule 30 mL for 10 days (cumulative dose 300 mL), the increase in non-fatal serious adverse events was more prominent11

  • human trialIn the subgroup of dosing schedule 30 mL for 10 days (cumulative dose 300 mL), the increase in non-fatal SAEs was more prominent12

  • human trialIn the dosing schedule of 30 mL for 10 days (cumulative dose 300 mL), the increase in non-fatal serious adverse events was more prominent13

  • human trialThe included studies tested varying doses and duration of Cerebrolysin treatment with follow-up ranging from 15 days to three years14

  • expert opinionAcute ischemic stroke: 30-50 mL IV daily for 10-21 days26

  • expert opinionTraumatic brain injury: 30 mL IV daily for 10-20 days26

Show the remaining 6

  • expert opinionVascular dementia/cognitive impairment: 10-30 mL IV or IM daily for 10-21 days, repeatable every 2-3 months26

  • expert opinionPediatric: 1-2 mL per 10 kg daily26

  • expert opinionMaximum single dose 50 mL26

  • expert opinionTypical dose 10–30 mL IV infusion daily for 10–20 day courses27

  • expert opinionThe preparation is administered by intravenous infusion, typically at doses of 10 to 30 mL per day over multi-week courses29

  • expert opinionClinical doses range from 10-30 mL/day IV for stroke/dementia; up to 50 mL/day for traumatic brain injury30

How the body handles it

Based on 1 animal finding, 14 expert opinion findings and 1 theoretical finding.

  • animalCerebrolysin molecules can be detected in neuronal tissue21

  • expert opinionPeptides like cerebrolysin are typically broken down in the gut without ever reaching the body or brain when given orally, and are thus given through injection3

  • expert opinionCerebrolysin prevents protection against excitotoxicity7

  • expert opinionCerebrolysin achieves reduction of free radicals7

  • expert opinionCerebrolysin achieves reduction of pro-apoptotic enzymes7

  • expert opinionCerebrolysin achieves modulation of inflammatory response7

  • expert opinionCerebrolysin achieves improvement of BBB integrity7

  • expert opinionOne ml contains 215.2 mg of Cerebrolysin concentrate in aqueous solution25

Show the remaining 8

  • expert opinionActive peptide fractions are <10,000 Da (Dalton)26

  • expert opinionPeptide fractions are rapidly hydrolyzed in plasma (minutes); biological effects on neurotrophic signaling persist days to weeks beyond dosing26

  • expert opinionUse bacteriostatic (BAC) water only for reconstitution; avoid saline which may cause precipitation27

  • expert opinionStore reconstituted solution refrigerated (2–8°C) and use within 28 days27

  • expert opinionThese peptide fragments can cross the blood-brain barrier and interact directly with neurons28

  • expert opinionEach milliliter of Cerebrolysin solution contains 215.2 mg of peptide concentrate30

  • expert opinionApproximately 75% of the preparation by weight consists of free L-amino acids, while the remaining ~25% is composed of biologically active peptides with molecular weights below 10,000 daltons30

  • theoreticalDue to its molecular structure, Cerebrolysin reaches the neurovascular unit directly in the brain21

Safety and side effects

Based on 33 human trial findings and 10 expert opinion findings.

  • human trialThe efficacy, tolerability, and safety of neuroreparative Cerebrolysin therapy has been confirmed in clinical trials involving adults with stroke and Alzheimer's disease1

  • human trialStudies suggest cerebrolysin is generally safe3

  • human trialCerebrolysin is safe for use up to three years with few adverse effects3

  • human trialAdverse effects from cerebrolysin are usually temporary and include headaches, weight loss, dizziness, anxiety, agitation, and feeling hot3

  • human trialThe rates of adverse effects were comparable between people receiving cerebrolysin versus placebo3

  • human trialNo significant group differences were seen in safety parameters between cerebrolysin and placebo4

  • human trialNo significant group differences were seen in any safety parameters5

  • human trialCerebrolysin is safe and well tolerated6

Show the remaining 35

  • human trialCerebrolysin had a higher rate of adverse effects compared to conventional treatment in acute ischemic stroke patients10

  • human trialCerebrolysin probably results in little to no difference in the total number of people with serious adverse events11

  • human trialCerebrolysin use shows an increase in the total number of people with non-fatal serious adverse events11

  • human trialCerebrolysin or similar peptide mixtures may result in little to no difference in the total number of people with adverse events11

  • human trialModerate-certainty evidence indicates a potential increase in non-fatal serious adverse events with Cerebrolysin use11

  • human trialCerebrolysin probably results in little to no difference in the total number of people with serious adverse events12

  • human trialThere is an increase in the total number of people with non-fatal serious adverse events12

  • human trialCerebrolysin or similar peptide mixtures may result in little to no difference in the total number of people with adverse events12

  • human trialCerebrolysin probably has no beneficial effect on the total number of people with serious adverse events12

  • human trialThere is a potential increase in non-fatal serious adverse events with Cerebrolysin use12

  • human trialCerebrolysin probably results in little to no difference in the total number of people with serious adverse events13

  • human trialThere is an increase in the total number of people with non-fatal serious adverse events with Cerebrolysin13

  • human trialCerebrolysin may result in little to no difference in the total number of people with adverse events13

  • human trialCerebrolysin results in little to no difference in non-death attrition13

  • human trialOnly one trial described mortality and reported no deaths14

  • human trialFour studies reported adverse events with no difference in rates of adverse effects between Cerebrolysin and control14

  • human trialNo significant difference in total serious adverse events with cerebrolysin versus placebo15

  • human trialIncrease in non-fatal serious adverse events with cerebrolysin compared to placebo15

  • human trialNo difference in total number of people with adverse events between cerebrolysin and placebo groups15

  • human trialCerebrolysin increased the risks of serious adverse events by at least one third compared to placebo in acute ischaemic stroke16

  • human trialNo difference in total number of people with adverse events between cerebrolysin and placebo groups16

  • human trialThere was no difference in the total number of adverse events between Cerebrolysin and placebo groups17

  • human trialOnly non-serious adverse events were observed in the included trials with no significant difference in occurrence between groups (RR 0.97, 95% CI 0.49 to 1.94)18

  • human trialNo difference in total number of adverse events between cerebrolysin and placebo groups (16.4% versus 10.3%)19

  • human trialCerebrolysin was generally well tolerated in clinical trials, with dizziness (or vertigo) being the most frequently reported adverse event20

  • expert opinionBecause cerebrolysin is purified from animal tissue, there is a risk of bacterial, viral, or fungal contamination of the product3

  • expert opinionCerebrolysin preserves a promising safety profile8

  • expert opinionCerebrolysin is safe and well tolerated25

  • expert opinionThe experience with Cerebrolysin during many years of clinical application, the information from post-marketing surveillance studies, the safety data from double-blind, placebo-controlled clinical trials and EVER's pharmacovigilance database demonstrate the excellent clinical safety profile25

  • expert opinionAccording to EMA classification, Cerebrolysin is in the SAFE category25

  • expert opinionReported adverse drug reactions are transient and mild in intensity25

  • expert opinionContraindications include hypersensitivity to components, epilepsy, and severe renal impairment25

  • expert opinionSide effects include headache, mild anxiety or restlessness, nasal irritation, sleep disturbance if dosed too close to bedtime, and rare mood changes or emotional lability27

  • expert opinionIn the United States, Cerebrolysin is not currently approved by the FDA for any medical indication28

  • expert opinionCerebrolysin has never been approved by the United States Food and Drug Administration (FDA)30

What people use it for

Based on 4 human trial findings, 3 human study findings and 13 expert opinion findings.

  • human trialCerebrolysin may be an effective and feasible way equivalent to stem cell therapy for communication defects in infants with severe perinatal brain insult1

  • human trialCerebrolysin was included among nine interventions evaluated for neuroprotective efficacy in acute ischemic stroke10

  • human trialCerebrolysin is widely used in the treatment of acute ischaemic stroke in Russia, Eastern Europe, China, and other Asian and post-Soviet countries12

  • human trialCerebrolysin may have positive effects on cognitive function and global function in elderly patients with vascular dementia of mild to moderate severity18

  • human studyImpaired cognitive functioning is a key feature of PTSD, including attention deficits and reduced processing speed, executive dysfunction, and impairments in verbal learning and memory9

  • human studyCognitive impairments in PTSD are significantly persistent and are largely similar in nature to neuropsychological impairments in neurodegenerative pathology9

  • human studyCerebrolysin, given as a series of daily intravenous infusions, is used as a potential intervention for vascular dementia14

  • expert opinionCerebrolysin is a multi-modal neuropeptide drug with a fast onset of action that helps to regain and maintain the independence of patients suffering from stroke, TBI, dementia and cognitive impairment2

Show the remaining 12

  • expert opinionCerebrolysin is approved in many European and Asian countries as an injection for treating stroke, traumatic brain injury, and dementia3

  • expert opinionIt remains unknown if cerebrolysin might prevent dementia or slow cognitive decline3

  • expert opinionCerebrolysin has neurorestorative properties that are thought to be effective in both the acute and chronic phases of stroke8

  • expert opinionCerebrolysin is widely used in the treatment of acute ischaemic stroke in Russia, China, and other Asian and post-Soviet countries17

  • expert opinionCerebrolysin is widely used in the treatment of acute ischaemic stroke in Russia and China19

  • expert opinionCerebrolysin is a multi-modal neuropeptide drug with a fast onset of action that helps to regain and maintain the independence of patients suffering from stroke, TBI, dementia and cognitive impairment25

  • expert opinionTherapeutic indications include cerebrovascular disorders, senile dementia of Alzheimer's type, vascular dementia, stroke, and craniocerebral trauma25

  • expert opinionCerebrolysin is approved in 35+ countries including Austria, Germany, Russia, China; NOT FDA-approved in the United States26

  • expert opinionApproved in Austria, Russia, China, South Korea, and other countries for Alzheimer's disease, post-stroke recovery, and traumatic brain injury27

  • expert opinionCerebrolysin is approved in more than 45 countries for conditions including ischemic stroke, traumatic brain injury (TBI), and various forms of dementia28

  • expert opinionCerebrolysin is approved for clinical use in over 50 countries30

  • expert opinionCerebrolysin is used frequently in neurorehabilitation clinics for neuroprotection following acute ischemic stroke31

Other findings

Based on 1 human study finding and 16 expert opinion findings.

  • human studyPTSD has an incidence of up to 12.5% among primary care patients9

  • expert opinionCerebrolysin is a mixture of peptides derived from the brains of pigs3

  • expert opinionCerebrolysin is not approved for use in the United States3

  • expert opinionCerebrolysin is a neuropeptide preparation consisting of amino acids and neuropeptides6

  • expert opinionCerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from pigs' brain tissue15

  • expert opinionCerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from pigs' brain tissue16

  • expert opinionCerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from pigs' brain tissue17

  • expert opinionCerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from pigs' brain tissue19

Show the remaining 9

  • expert opinionCerebrolysin is a parenteral biological drug consisting of peptides and amino acids21

  • expert opinionExcipients are sodium hydroxide and water for injection25

  • expert opinionCerebrolysin is not registered with the U.S. Food and Drug Administration (FDA) and is not approved for sale or distribution in the United States25

  • expert opinionStorage: room temperature (below 25°C), protect from light; do not freeze. Once drawn or diluted: administer immediately; do not store reconstituted solution26

  • expert opinionNot FDA-approved in the US27

  • expert opinionCerebrolysin was first developed in 1949 by Austrian professor Gerhart Harrer and received regulatory approval in Austria in 195428

  • expert opinionCerebrolysin is a proprietary extract derived from purified porcine (pig) brain tissue, manufactured exclusively by EVER Neuro Pharma, headquartered in Austria29

  • expert opinionCerebrolysin (FPF-1070) is an injectable preparation of low-molecular-weight neuropeptides and free amino acids produced by standardized enzymatic proteolysis of lipid-free porcine brain proteins30

  • expert opinionCerebrolysin was first developed in the 1940s and further refined in the 1970s30

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Contested

Sources sharply disagree on whether Cerebrolysin actually benefits acute ischemic stroke.

A single 100-patient randomized trial (Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial) reported superiority over placebo at day 30 on the NIH Stroke Scale, the modified Rankin Scale, and the Clinical Global Impression, but it did not measure survival. A separate network meta-analysis (Efficacy analysis of neuroprotective drugs in patients with acute ischemic stroke based on network meta-analysis) placed Cerebrolysin among interventions associated with reduced mortality, and manufacturer materials (Product Monograph; Improving Patient Recovery) claim proven efficacy and a higher survival rate. In contrast, successive Cochrane systematic reviews (Cerebrolysin for acute ischaemic stroke) conclude that Cerebrolysin probably makes little to no difference to all-cause death (RR 0.96, 95% CI 0.65 to 1.41; moderate-certainty evidence), that no clinical benefit is demonstrated, and that routine use is not supported; these reviews also found a probable increase in non-fatal serious adverse events.

Contested

Manufacturer describes an 'excellent' safety profile while Cochrane reviews flag increased non-fatal serious adverse events.

Manufacturer and vendor sources (Role and Impact of Cerebrolysin for Ischemic Stroke Care – ScienceOpen,Product Monograph,A comprehensive overview of Cerebrolysin®,[PDF] Product Monograph | Cerebrolysin) describe Cerebrolysin as safe, well-tolerated, and in the EMA 'SAFE' category. However, multiple Cochrane reviews (Cerebrolysin for acute ischaemic stroke,Superpower,Cerebrolysin for acute ischaemic stroke.,Cerebrolysin for acute ischaemic stroke.,Cerebrolysin for acute ischaemic stroke.,Cerebrolysin for acute ischaemic stroke.) report a statistically significant increase in non-fatal serious adverse events (RR ~2.39), more prominent at the 30 mL/10-day cumulative 300 mL schedule (RR ~2.87), and Efficacy analysis of neuroprotective drugs in patients with acute ischemic stroke based on network meta-analysis. notes a higher rate of adverse effects versus conventional treatment.

Limited evidence

Vascular dementia and Alzheimer's benefits are reported but authors caution evidence is insufficient for routine recommendation.

Meta-analyses and reviews (Cerebrolysin for vascular dementia.,Cerebrolysin for vascular dementia.,Cerebrolysin: a review of its use in dementia.) report cognitive and global-function benefits in vascular dementia and Alzheimer's, but explicitly note the limited number of trials, varied treatment durations, and short-term follow-up preclude recommending routine use; Cerebrolysin & Your Brain | Cognitive Vitality | Alzheimer's Drug Discovery Foundation adds that the memory effect is lower than currently approved Alzheimer's drugs and dementia-prevention benefit is unknown.

Single source

The dramatic infant perinatal brain-injury results come from a single trial.

The reported large improvements in social, speech, symbolic, and total scores in infants with severe perinatal brain insult, and the claim of equivalence to stem cell therapy, derive solely from one trial (:: JCN :: Journal of Clinical Neurology) and are not corroborated by other sources.

Other

Reported composition percentages and study/patient counts vary across sources.

Composition is described as ~75% amino acids/25% peptides (Cerebrolysin: Research Evidence & Safety Profile | PeptideInsight) versus ~85%/15% ([Protective effect of FPF 1070 (cerebrolysin) on delayed neuronal death in the gerbil--detection of hydroxyl radicals with salicylic acid].). The size of the evidence base is variously stated as 87 studies/17,000 patients (Improving Patient Recovery), 160+ studies/8,000 patients (Cerebrolysin: Research Evidence & Safety Profile | PeptideInsight), or 200 trials/15,000 patients (Cerebrolysin Peptide: Complete Guide to Brain Health (2026)), and approved-country counts range from 35+ to 50+. These discrepancies appear largely in manufacturer/vendor materials.

Limited evidence

Many mechanistic and enhancement claims rely on low-tier vendor sources or preclinical (in vitro/animal) data.

Neurotrophic-mimicry, receptor-activation, mood/anxiolytic, and cognitive-enhancement claims are frequently drawn from tier-3 commercial/vendor pages (Cerebrolysin: Research Evidence & Safety Profile | PeptideInsight,Cerebrolysin - Clinical Guide | PeptidePrescriber,Cerebrolysin Peptide: Complete Guide to Brain Health (2026),Cerebrolysin (FPE 1070) — Dosing, Side Effects, FDA Status & Research | PeptIQ | PeptIQ,Superpower) or from in vitro and animal studies (Improving Patient Recovery,Cerebrolysin - Clinical Guide | PeptidePrescriber,Cerebrolysin & Your Brain | Cognitive Vitality | Alzheimer's Drug Discovery Foundation,Neurotrophic effects of FPF-1070 (Cerebrolysin) on cultured neurons from chicken embryo dorsal root ganglia, ciliary ganglia, and sympathetic trunks.,[Cerebrolysin peptides as mood stabilizers].,[Protective effect of FPF 1070 (cerebrolysin) on delayed neuronal death in the gerbil--detection of hydroxyl radicals with salicylic acid].) rather than human outcome trials; effects seen in cells or animals may not translate to clinical benefit.

Using it with other compounds

Check a stack
  • SelankComplementary

    No documented conflict

    Selank supports BDNF signaling, modulates monoamines and adds GABAergic anxiolytic tone plus immunomodulation, complementing Cerebrolysin's neurotrophic and anti-inflammatory profile. A reasonable nootropic/anxiolytic pairing, though only anecdotally documented together.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The mechanism descriptions clearly establish all three claimed shared dimensions: (1) dopaminergic_system—both peptides modulate dopamine (Cerebrolysin via kinase inhibition affecting dopaminergic system; Selank via dopamine receptor modulation and monoamine metabolism); (2) anti_inflammatory—both are tagged with anti_inflammatory effects (Cerebrolysin via TNF-α downregulation and microglia modulation; Selank via immunomodulatory and cytokine signaling); (3) BDNF_signaling—both explicitly upregulate or support BDNF (Cerebrolysin via BDNF upregulation pathway; Selank via BDNF signaling pathway). The explanation correctly identifies complementary mechanisms: Cerebrolysin provides broad neurotrophic/neuroprotective effects while Selank adds GABAergic anxiolytic tone and enkephalinase inhibition. The proposed relationship type (complementary) is justified by the distinct but non-overlapping primary mechanisms (Cerebrolysin's TrkA/TrkB targeting vs. Selank's GABA-A modulation) combined with shared downstream effects on the three dimensions. The caveat about anecdotal documentation does not undermine the mechanistic support.

    Shares dopaminergic system · anti inflammatory · BDNF signaling

  • SemaxComplementary

    May be complementary

    Both upregulate BDNF and act via TrkB, reduce neuroinflammation, and modulate dopaminergic tone, but Semax (an ACTH fragment) adds enkephalinase inhibition and its own neurotrophin induction. Different upstream triggers converging on the same neuroprotective/nootropic output make them a plausible complementary nootropic pair. Human combination data are lacking.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The mechanism descriptions clearly establish all four claimed shared dimensions: (1) BDNF_signaling—both explicitly upregulate BDNF and target TrkB receptor; (2) dopaminergic_system—Cerebrolysin lists kinase inhibition affecting dopaminergic system and dopaminergic_system tag; Semax lists dopaminergic modulation and dopaminergic_system tag; (3) anti_inflammatory—both reduce neuroinflammation (Cerebrolysin via microglia modulation and TNF-α downregulation; Semax via immune modulation and NF-κB modulation); (4) neurogenesis—both have neurogenesis tags and mechanisms supporting it. The explanation correctly identifies convergence on neuroprotective/nootropic outcomes via different upstream mechanisms (Cerebrolysin via TrkA/TrkB/GFRα1 and multiple kinase pathways; Semax via μ-opioid receptor, melanocortin receptors, and enkephalinase inhibition). The claim that Semax adds enkephalinase inhibition (distinct from Cerebrolysin's endorphinergic effects via peptide fragments) is supported by the mechanisms. The 'complementary' relationship type is justified by the shared dimensions combined with mechanistically distinct upstream triggers converging on similar outputs, which is the hallmark of complementarity.

    Shares dopaminergic system · anti inflammatory · neurogenesis · BDNF signaling

  • EpithalonComplementary

    No documented conflict

    Epithalon contributes antioxidant, geroprotective and neurogenic effects with mitochondrial ROS modulation, complementing Cerebrolysin's neurotrophic and energy-metabolism support. Different mechanisms converging on neuronal health; combination evidence is anecdotal.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly support the claimed shared dimensions. For mitochondrial_function: Cerebrolysin explicitly includes 'mitochondrial_function' tag and 'Improved neuronal energy metabolism' effect; Epithalon includes 'mitochondrial_function' tag and 'Antioxidant / mitochondrial ROS modulation' pathway. For neurogenesis: both peptides explicitly list 'neurogenesis' in their approved tags and describe neurogenic effects (Cerebrolysin: 'neurogenesis and synaptogenesis'; Epithalon: 'Neuroprotective and neurogenic effects'). The explanation accurately characterizes their mechanisms as complementary—Epithalon targets cellular senescence and oxidative stress at the mitochondrial level while Cerebrolysin provides neurotrophic support and metabolic enhancement—representing different but convergent approaches to neuronal health. The mechanisms do not contradict this relationship; they support it.

    Shares mitochondrial function · neurogenesis

  • SS-31Complementary

    May be complementary

    SS-31 protects mitochondrial energy production and reduces oxidative stress at the cardiolipin level, while Cerebrolysin improves neuronal energy metabolism and provides neurotrophic support. Pairing a targeted mitochondrial protector with a neurotrophic mixture addresses neuroprotection from two angles. Combination evidence is anecdotal.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly establish the three claimed shared dimensions: (1) mitochondrial_function—SS-31 directly targets cardiolipin and ETC supercomplexes to improve ATP synthesis and mitochondrial structure; Cerebrolysin improves neuronal energy metabolism and is tagged with mitochondrial_function. (2) anti_inflammatory—SS-31 modulates inflammation/pyroptosis; Cerebrolysin explicitly includes anti-inflammatory modulation of microglia and TNF-α downregulation. (3) BDNF_signaling—both are explicitly tagged with BDNF_signaling, and SS-31's mechanisms include BDNF synaptic signaling while Cerebrolysin upregulates BDNF. The proposed 'complementary' relationship is justified: SS-31 provides targeted mitochondrial protection at the cardiolipin/ETC level, while Cerebrolysin provides broader neurotrophic and neuroprotective effects including energy metabolism support. These mechanisms operate on overlapping but distinct targets and pathways, supporting a complementary rather than redundant pairing. The explanation accurately reflects both mechanisms.

    Shares mitochondrial function · anti inflammatory · BDNF signaling

  • HumaninComplementary

    No documented conflict

    Both support neuronal survival through anti-apoptotic Bcl-2-family and PI3K/Akt survival signaling, reduced neuroinflammation, and improved neuronal energy metabolism, but via different entry points — cerebrolysin supplies neurotrophic peptide fragments acting on Trk receptors, while humanin acts as a mitokine through its gp130/STAT3 cytoprotective pathway. They target overlapping neuroprotective endpoints by distinct upstream routes.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The mechanisms clearly establish complementary action on shared dimensions. Both peptides demonstrate: (1) mitochondrial_function—humanin explicitly acts as a 'mitokine' enhancing mitochondrial biogenesis/bioenergetics, cerebrolysin improves neuronal energy metabolism; (2) anti_inflammatory—humanin reduces pro-inflammatory cytokines via JAK2/STAT3, cerebrolysin modulates microglia and downregulates TNF-α; (3) mTOR_PI3K—both activate PI3K/Akt survival signaling (humanin directly, cerebrolysin via NTF pathway); (4) IGF1_signaling—humanin engages IGF-I signaling and IGFBP-3, cerebrolysin upregulates IGF-1. The proposed explanation accurately reflects the mechanisms: both converge on anti-apoptotic Bcl-2 family modulation and neuronal survival but via distinct upstream routes (humanin through gp130/STAT3 cytoprotection as a mitokine; cerebrolysin through Trk receptor-mediated neurotrophic factor mimicry). The shared dimensions are explicitly supported by the provided mechanism material, and the complementary relationship is justified by their different entry points achieving overlapping neuroprotective endpoints.

    Shares mitochondrial function · anti inflammatory · mTOR PI3K · IGF1 signaling

  • NoopeptComplementary

    May be complementary

    Noopept raises BDNF/NGF, activates TrkB, and provides antioxidant/anti-inflammatory neuroprotection, echoing Cerebrolysin's neurotrophic and mitochondrial-support actions through a distinct dipeptide mechanism. The two can reinforce cognitive and neuroprotective signaling; combination evidence is anecdotal.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The mechanism descriptions clearly establish the three claimed shared dimensions: (1) mitochondrial_function—both peptides are tagged with this and show antioxidant/anti-inflammatory actions supporting mitochondrial health; (2) anti_inflammatory—both explicitly target anti-inflammatory pathways (Cerebrolysin via TNF-α downregulation and microglia modulation; Noopept via antioxidant and anti-inflammatory action); (3) BDNF_signaling—both are tagged with this and their mechanisms confirm it (Cerebrolysin upregulates BDNF; Noopept activates BDNF/NGF signaling via TrkB). The explanation correctly identifies distinct mechanisms (Cerebrolysin's multi-target neurotrophic approach vs. Noopept's HIF-1/TrkB pathway) that converge on overlapping neuroprotective and cognitive outcomes, which justifies the 'complementary' relationship type. The claim that they can reinforce each other through these shared dimensions is supported by the parallel but mechanistically distinct pathways described.

    Shares mitochondrial function · anti inflammatory · BDNF signaling

  • DavunetideComplementary

    May be complementary

    Both act on tau hyperphosphorylation and neuroprotection through PI3K/Akt–GSK3 signaling, but Davunetide works primarily by stabilizing microtubules while Cerebrolysin works via neurotrophic mimicry. Different molecular handles on the same neurodegenerative target make them complementary. Combination data are preclinical/anecdotal.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The mechanisms clearly establish both shared dimensions and complementary action. Both peptides: (1) target PI3K/Akt–GSK3 signaling (explicitly listed in both mechanism descriptions), (2) reduce tau hyperphosphorylation (Davunetide directly via microtubule-tau crosstalk and GSK-3; Cerebrolysin via GSK3 modulation and APP/tau processing), (3) exhibit anti-inflammatory and anti-apoptotic effects (both approved tags match), and (4) promote neuroprotection. The explanation correctly identifies their mechanistic distinction: Davunetide's primary action is microtubule stabilization via EB/tubulin/tau interaction, while Cerebrolysin acts via neurotrophic factor mimicry and multi-target kinase modulation. These represent different molecular entry points converging on shared downstream pathways (PI3K/Akt, GSK-3, tau regulation), which justifies the 'complementary' classification. Both shared dimensions are explicitly supported by the approved tags and pathway descriptions provided.

    Shares anti inflammatory · mTOR PI3K

  • CortexinSame mechanism

    Worth caution

    Both are enzymatically-digested animal-brain peptide mixtures (bovine/porcine cortex) working as broad neurotrophic-factor mimics — anti-apoptotic, anti-excitotoxic, anti-inflammatory, and pro-neuroplasticity. Because they occupy almost the same conceptual niche, running both together is largely redundant rather than additive, and it becomes impossible to tell which product is responsible for any benefit or side effect. Most users should pick one crude neurotrophic mixture rather than stack the two.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The mechanism descriptions clearly establish substantial overlap in the shared dimensions claimed. Both peptides are enzymatically-processed animal-brain extracts (bovine cortex for Cortexin, porcine brain for Cerebrolysin) containing small peptides and amino acids under ~10,000 Da. The four shared dimensions are all explicitly supported: (1) anti_inflammatory—both list anti-inflammatory effects and pathways; (2) neurogenesis—both explicitly target neurogenesis and neuroplasticity; (3) dopaminergic_system—both include dopaminergic modulation in their approved tags and pathways; (4) BDNF_signaling—both explicitly list BDNF_signaling as an approved tag and describe neurotrophic-factor mimicry. Both also share anti-apoptotic and anti-excitotoxic mechanisms. The explanation's characterization of them as 'broad neurotrophic-factor mimics' with overlapping neuroprotective profiles is directly supported by the parallel targeting of neurotrophic pathways (BDNF, neurotrophic factors), anti-inflammatory effects, and neurogenesis. The claim that they occupy a similar conceptual niche is justified by the mechanism material.

    Shares anti inflammatory · neurogenesis · dopaminergic system · BDNF signaling

  • P21Complementary

    May be complementary

    Cerebrolysin stimulates BDNF and signals through TrkB and PI3K/Akt survival pathways, while P21 (a CNTF fragment) drives BDNF expression that also feeds TrkB and neurogenesis. They reach the same BDNF/TrkB neuroplasticity endpoint from different starting points, so they can reinforce each other's neurotrophic and pro-neurogenic effects. Evidence for the specific combination is anecdotal.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly establish the three claimed shared dimensions. Cerebrolysin targets TrkB, upregulates BDNF/VEGF/IGF-1, activates PI3K/AKT survival signaling, and promotes neurogenesis (approved tags: BDNF_signaling, mTOR_PI3K, neurogenesis). P21 induces BDNF expression, signals via TrkB, activates PI3K/Akt and Akt–GSK-3beta pathways, and stimulates adult hippocampal neurogenesis (approved tags: BDNF_signaling, mTOR_PI3K, neurogenesis). The explanation correctly identifies that both converge on BDNF/TrkB and PI3K/Akt pathways despite different mechanisms of action (Cerebrolysin as a multi-target neuroprotective mixture; P21 as a CNTF-mimetic fragment). The 'complementary' relationship type is justified: they operate through overlapping downstream pathways (BDNF/TrkB, PI3K/Akt, neurogenesis) but via distinct upstream mechanisms, supporting potential synergistic or reinforcing effects. The caveat about anecdotal evidence for the specific combination does not undermine the mechanistic justification for the relationship itself.

    Shares neurogenesis · mTOR PI3K · BDNF signaling

  • KlothoComplementary

    No documented conflict

    Klotho has preclinical cognitive/synaptic-enhancing effects (via NMDA GluN2B modulation) plus neuronal anti-inflammatory and antioxidant activity, while cerebrolysin supplies neurotrophic support (TrkB/BDNF, IGF-1) and anti-apoptotic signaling. Different neuroprotective mechanisms converging on brain resilience make them a plausible complementary pairing for cognitive support.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms explicitly support the claimed shared dimensions: (1) Anti-inflammatory: Klotho shows NF-κB modulation and anti-inflammatory activity; Cerebrolysin shows anti-inflammatory modulation of microglia and TNF-α downregulation. Both are tagged 'anti_inflammatory'. (2) IGF1_signaling: Klotho targets the IGF-1/insulin receptor signaling axis; Cerebrolysin upregulates IGF-1 and is tagged 'IGF1_signaling'. The explanation accurately describes complementary mechanisms—Klotho's NMDA/synaptic enhancement and antioxidant pathways (Nrf2, FoxO) paired with Cerebrolysin's neurotrophic factor mimicry (TrkB, BDNF upregulation) and anti-apoptotic signaling (PI3K/AKT, Bcl-2)—that could plausibly converge on neuroprotection. The mechanisms do not contradict this relationship; they support convergence on cognitive/brain resilience through distinct but complementary pathways.

    Shares anti inflammatory · IGF1 signaling

  • PinealonComplementary

    No documented conflict

    Pinealon is a short bioregulator peptide reported to reduce neuronal oxidative stress and apoptosis and support dendritic/neuroplastic changes, overlapping with Cerebrolysin's neurogenic and neuroprotective goal via a different (proposed gene-regulatory) mechanism. Combination is anecdotal.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms describe effects supporting neurogenesis and neuroprotection through distinct pathways. Cerebrolysin achieves this via neurotrophic factor mimicry (TrkA/TrkB, BDNF/VEGF/IGF-1 upregulation, PI3K/AKT signaling, anti-apoptotic pathways). Pinealon achieves similar neuroprotective outcomes through proposed gene-regulatory mechanisms (DNA/promoter binding affecting CASP3, GAP43, antioxidant enzyme expression, MAPK/ERK, PI3K/Akt, caspase-3 inhibition, ROS reduction). Both are tagged with neurogenesis and both reduce apoptosis and oxidative stress. The mechanisms justify the claim of complementary action on a shared dimension (neurogenesis/neuroprotection) via mechanistically distinct routes—one primarily via growth factor signaling, the other via transcriptional/gene-regulatory pathways. The explanation accurately reflects the provided mechanism material.

    Shares neurogenesis

Safety and side effects

Overall Tolerability

Cerebrolysin was generally well tolerated in clinical trials, with dizziness (or vertigo) being the most frequently reported adverse event. In the acute ischemic stroke RCT, no significant group differences were seen in any safety parameters between Cerebrolysin and placebo. Reported adverse effects are usually temporary and may include headaches, weight loss, dizziness, anxiety, agitation, and feeling hot; some sources also list nasal irritation, sleep disturbance if dosed close to bedtime, and rare mood changes or emotional lability. Some studies suggest it is generally safe, including use up to three years with few adverse effects.

Serious Adverse Events — A Contested Point

There is a genuine disagreement in the literature:

  • The manufacturer describes an excellent clinical safety profile (citing an EMA 'SAFE' category), supported by post-marketing surveillance, placebo-controlled trials and pharmacovigilance data, with adverse drug reactions reported as transient and mild.
  • Cochrane analyses, while finding probably little to no difference in the total number of people with serious adverse events (RR 1.16, 95% CI 0.81–1.66) or total adverse events (RR 1.03, 95% CI 0.92–1.14), report a statistically significant increase in non-fatal serious adverse events (RR ~2.39, 95% CI 1.10–5.23; earlier estimates RR 2.47 and 2.15). One analysis found serious adverse events increased by at least one third versus placebo (62/589 vs 46/600; RR 1.37). The signal was more prominent at the 30 mL/10-day cumulative 300 mL schedule (RR 2.87, 95% CI 1.24–6.69). A network meta-analysis also noted a higher rate of adverse effects versus conventional treatment.
  • In vascular dementia trials, only non-serious adverse events were observed, with no significant difference between groups (RR 0.97, 95% CI 0.49–1.94; RR 0.91, 95% CI 0.29–2.85). An earlier small review found adverse events higher but not statistically different (16.4% vs 10.3%; RR 1.62, 95% CI 0.69–3.82).

Contraindications and Theoretical Risks

Reported contraindications include hypersensitivity to the components, epilepsy, and severe renal impairment. Because Cerebrolysin is purified from animal (porcine) tissue, there is a theoretical risk of bacterial, viral or fungal contamination of the product.

Bottom Line

Routine tolerability appears acceptable in most trials, but the increased non-fatal serious adverse event signal from systematic reviews — especially at higher cumulative dosing — should be weighed against manufacturer safety claims. This is not medical advice; the profile reports what the research and sources state.

Reconstitution and handling

Formulation

Cerebrolysin is supplied as an aqueous solution; each milliliter contains 215.2 mg of peptide concentrate, with sodium hydroxide and water for injection as excipients. Because peptides are typically broken down in the gut when given orally, it is administered by injection or infusion, not by mouth.

Reported Administration Methods

  • IV injection: up to 10 mL undiluted, given slowly over about 3 minutes.
  • IV infusion: 10–50 mL diluted to at least 100 mL (compatible infusion solution), infused over 15–60 minutes.
  • Intramuscular injection: up to about 5 mL.
  • Pediatric dosing (reported): 1–2 mL per 10 kg body weight daily.

Reported Dosing Regimens (by indication)

  • Acute ischemic stroke: 30–50 mL IV daily for 10–21 days (manufacturer: up to 21 days); maximum single dose 50 mL. Note that Cochrane analyses associated the 30 mL/10-day (cumulative 300 mL) schedule with a more prominent increase in non-fatal serious adverse events (RR 2.87).
  • Traumatic brain injury: up to 50 mL/day, or 30 mL IV daily for 10–20 days (up to 30 days duration).
  • Dementia / vascular cognitive impairment: 5–30 mL (typically 10–30 mL) IV or IM daily for 10–21 days, repeatable every 2–3 months (about 2–4 cycles per year).

In Cochrane-reviewed vascular dementia studies, doses and durations varied widely, with follow-up ranging from 15 days to three years.

Storage and Handling

Storage guidance from sources: keep at room temperature below 25°C, protect from light, and do not freeze. Sources differ on reconstituted/diluted solution handling — some community/vendor sources advise reconstituting only with bacteriostatic water (avoiding saline to prevent precipitation) and refrigerating the reconstituted solution at 2–8°C for up to 28 days, whereas regulatory sources advise administering the drawn/diluted solution immediately. The regulatory guidance is the more conservative and appropriate default.

Note

These figures are a faithful restatement of what the cited sources report and are not a recommendation or dosing instruction. Cerebrolysin is not FDA-approved and is administered parenterally in clinical settings in the countries where it is registered.

Sources

Ordered by evidence quality — the strongest first.

  1. :: JCN :: Journal of Clinical Neurology(opens in a new tab)
    Tier 1Web · thejcn.com
  2. [PDF] Product Monograph | Cerebrolysin(opens in a new tab)
    Tier 1Web · cerebrolysin.com
  3. Cerebrolysin & Your Brain | Cognitive Vitality | Alzheimer's Drug Discovery Foundation(opens in a new tab)
    Tier 1Web · alzdiscovery.org
  4. Efficacy and safety of Cerebrolysin treatment in early recovery ...(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov
  5. Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial - PMC(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov
  6. Improving Patient Recovery(opens in a new tab)
    Tier 1Web · cerebrolysin.com
  7. Product Monograph(opens in a new tab)
    Tier 1Web · cerebrolysin.com
  8. Role and Impact of Cerebrolysin for Ischemic Stroke Care – ScienceOpen(opens in a new tab)
    Tier 1Web · scienceopen.com
  9. [Cognitive impairment in post-traumatic stress disorder].(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  10. Efficacy analysis of neuroprotective drugs in patients with acute ischemic stroke based on network meta-analysis.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  11. Cerebrolysin for acute ischaemic stroke(opens in a new tab)
    Tier 1Web · doi.org · 2023
  12. Cerebrolysin for acute ischaemic stroke.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  13. Cerebrolysin for acute ischaemic stroke.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2020
  14. Cerebrolysin for vascular dementia.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2019
  15. Cerebrolysin for acute ischaemic stroke.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2017
  16. Cerebrolysin for acute ischaemic stroke.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2016
  17. Cerebrolysin for acute ischaemic stroke.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2015
  18. Cerebrolysin for vascular dementia.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2013
  19. Cerebrolysin for acute ischaemic stroke.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2010
  20. Cerebrolysin: a review of its use in dementia.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2009
  21. Mode of Action(opens in a new tab)
    Tier 2Web · cerebrolysin.com
  22. [Cerebrolysin peptides as mood stabilizers].(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2019
  23. Neurotrophic effects of FPF-1070 (Cerebrolysin) on cultured neurons from chicken embryo dorsal root ganglia, ciliary ganglia, and sympathetic trunks.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2000
  24. [Protective effect of FPF 1070 (cerebrolysin) on delayed neuronal death in the gerbil--detection of hydroxyl radicals with salicylic acid].(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 1993
  25. A comprehensive overview of Cerebrolysin®(opens in a new tab)
    Tier 3Web · cerebrolysin.com
  26. Cerebrolysin - Clinical Guide | PeptidePrescriber(opens in a new tab)
    Tier 3Web · peptideprescriber.com
  27. Cerebrolysin (FPE 1070) — Dosing, Side Effects, FDA Status & Research | PeptIQ | PeptIQ(opens in a new tab)
    Tier 3Web · peptiq.io
  28. Cerebrolysin Peptide: Complete Guide to Brain Health (2026)(opens in a new tab)
    Tier 3Web · rwacenter.com
  29. Superpower(opens in a new tab)
    Tier 3Web · superpower.com
  30. Cerebrolysin: Research Evidence & Safety Profile | PeptideInsight(opens in a new tab)
    Tier 3Web · peptideinsight.com · 2026
  31. Current neuroprotective agents in stroke.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2024